Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

Q3 highlights: * Patients without previous exposure to biologics ** Patients with an inadequate response to TNF inhibitors Third quarter 2024 financial results As of September 30, 2024, MoonLake held ...

A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ATM ...

The severe asthma market is fueled by the rising prevalence of the condition, particularly in urban areas, alongside the emergence of innovative therapies ...

Among patients with rheumatoid arthritis, JAK inhibitors were slightly more effective for reducing pain at 3 and 12 months when compared with TNF inhibitors.

Tumors outside the central nervous system (CNS) did respond but the failure to shrink brain tumors took away TNG908’s raison d'etre. Tango has another MTA-cooperative PRMT5 inhibitor, TNG462, for ...

A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 ...

The lesion-specific 12-month cumulative incidence of radiographic radiation necrosis was 3.5% in the combination arm vs 3.2% in the immune checkpoint inhibitor–first arm. Although combining the two ...

The use of IL-17 inhibitors in patients with psoriasis was associated with an increased risk for fungal infections when compared with other biologics.

Tumour Necrosis Factor TNF is crucial for defence but can drive chronic inflammation linked to arthritis and autoimmune diseases when overproduced ...

INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness ...